Steatohepatitis | Topics

Transcriptomic landscape analysis reveals a persistent DNA damage response in metabolic dysfunction-associated steatohepatitis post-dietary intervention

Metabolic dysfunction-associated steatohepatitis (MASLD) exhibits persistent activation of the DNA damage response (DDR) and its primary transcription factor P53 even after dietary reversal. Elevated P53 levels correlate with hepatocyte ballooning, suggesting a link between DDR signaling and MASLD recurrence.

A novel approach to combat fatty liver disease

Researchers found inhibiting ACMSD increases NAD+ levels, reducing inflammation and fibrosis in mouse models of MASLD/MASH. Boosting NAD+ production could protect against severe liver damage and cirrhosis.

Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease

Researchers explore antidiabetic agents, PPAR agonists, FXR agonists, and other novel compounds to target MASLD pathogenesis. Combination therapies may enhance therapeutic efficacy while minimizing side effects, offering new hope to patients at risk of advanced liver disease.